From Across the Pond: Expert Insight on Life Science Start-ups

Add this event to your calendar:
07/11/2017 17:00 07/11/2017 20:00 America/Toronto From Across the Pond: Expert Insight on Life Science Start-ups JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1 JLABS @ Toronto false DD/MM/YYYY

From Across the Pond: Expert Insight on Life Science Start-ups

JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1

November 07, 2017 from 17:00 PM to 20:00 PM (EST)

$10 - $35

It can be tricky to communicate the full potential of your discoveries without spilling the secret sauce. Join us for a special presentation from Jeanne Bolger on learning the tricks of the trade in preparing a non-confidential deck and executive summary. She will share practical tips on becoming more effective in communicating your story to Angel investors and VCs, increasing your chances of successful fundraising.

After Jeanne’s presentation, join us for a panel discussion on becoming a life science entrepreneur in both Canada and Ireland.

Jeanne Bolger | VP, Venture Investments, Johnson & Johnson Innovation - JJDC read bio»
Alan Hobbs | Manager High Potential Start Ups, Enterprise Ireland read bio»
Sandra Ganly | Operations Manager , BioInnovate read bio»
Anne O’Riordan | Global Industry Senior Managing Director, Accenture read bio»

4:00 | Registration Opens and Networking
4:30 | Presentation
5:15 | Q&A
5:30 | Panel
6:00 | Cocktail Reception
7:00 | Program Close

Who should attend:
This event is ideal for inventors in academic centers and hospitals, and early stage healthcare start-ups in the pharma, medical device, consumer health and digital innovation areas.

$15 | General Public
Includes presentation, Q&A, and lunch.

JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, Ontario

Speaker Biographies:
Jeanne Bolger | VP, Venture Investments, Johnson & Johnson Innovation - JJDC
Jeanne joined Johnson & Johnson Innovation - JJDC as Vice President, Venture Investments, in February 2013. She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne's responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.
Jeanne has over 25 years of pharmaceutical industry experience in management roles across R+D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson's Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK.
In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer's disease.
Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Alan Hobbs | Manager High Potential Start Ups, Enterprise Ireland
Alan manages the Irish Government’s lifescience High Potential Start-Up team who work with the best emerging Bio, Pharma and Medical Device companies in Ireland. He has 27 years global experience living and working in China, Silicon Valley, Taiwan, Korea and Ireland. Alan started his career working with “C” level executives in US and Asian Multinationals, selling Ireland as a HQ for their EMEA activities, he crossed over to the domestic side of economic development with roles in High Growth Markets, Corporate Communications and the Food sector. MBA graduate from Trinity College, currently lives in Dublin with Yvonne, Thomas and Conor, cats (Nellie and Bill) and Peanut the dog.

Enterprise Ireland is the Agency of the Irish Government responsible for the Development of Irish Industry. They work with 5000 clients across a wide range of sectors to help entrepreneurs start, scale and succeed in Global markets. More information available at:

Sandra Ganly | Operations Manager , BioInnovate
Sandra Ganly is a biomedical engineer with 14 years industrial and innovative product design experience in the medical device industry, progressing from technician and engineering roles to leadership positions in both Industry and Academia. She conducted her PhD research in Next Generation Coronary Stents and holds a senior research fellow position in NUI Galway’s Cardiovascular Research Institute where she continues her Preventive Cardiology and Risk-factor research interests. Since 2008, Sandra has maintained a role at the interface of academic, business and clinical communities, successfully managing multi-disciplinary projects for the benefit of the Medtech sector in Ireland – including the establishment of a Masters in Medical Technology Regulatory Affairs and BioInnovate Ireland - a Medical Device Innovation programme modelled on the prestigious Stanford Biodesign programme. As BioInnovate’s commercial lead, Sandra has assisted 19 technology solutions transition from their proof-of-concept origins in academia to raising investment in the market. Sandra was recently appointed as a Director in a newly funded mentor-centric Medtech Accelerator, BioExel, which aims to further support early stage and has a longer-term ambition to raise a consortium fund with Angels, Corporates and Government for Medtech start-ups in Ireland. Sandra is also the Chief Technology Officer for her own technology company, Contego Medical, focused on developing innovative solutions for unmet clinical needs in Sports-acquired Brain Injury.

Anne O’Riordan | Global Industry Senior Managing Director, Accenture
Anne is the global Industry Senior Managing Director for Accenture’s Life Sciences business and a global client lead. She has been with Accenture for 27 years. Over this period she has worked across the US, Europe and Asia with global companies transforming their business and operating models, to meet changing market and portfolio needs. She has been in China since 2007 and has been on the board of the global Products Operating Group of Accenture since 2006. She has published numerous articles over the past 20+ years. Her most recent publication is a book entitled ‘Healthcare Disrupted: Next Generation Business Models and [email protected] (Wiley Feb 2016)”.  Based in Hong Kong, Ms. O’Riordan is a member of The Women’s Foundation, the 30% Club and co-chair of the Women of Influence Committee at the American Chamber of Commerce.

JLABS @ Toronto

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit or follow @JNJInnovation.

Event contact

Related content